[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641680":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":18,"centralContacts":19,"locations":25,"responsibleParty":38,"collaborators":18,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":18,"enrollmentInfo":49,"targetDuration":18,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":64,"whyStopped":18,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Nantes University Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Pain sensitization parameter testing","EXPERIMENTAL","Pre-inclusion visit (routine care consultation): Verification of inclusion and exclusion criteria.\n\nInclusion visit (Day 0): Consent signing, questionnaires (ConvergencePP Score\u002FCentral Sensitization Inventory, DN4), and a series of tests, followed by the application of the high-concentration capsaicin patch (PCHC) (performed during routine care).\n\nDay 30 visit (±7 days): Questionnaires (same as V1 + PGI-c) and a series of tests.",[13],"Other: Quantitative Sensory Testing and questionnaires",[15],{"type":6,"name":16,"description":16,"armGroupLabels":17,"otherNames":18},"Quantitative Sensory Testing and questionnaires",[9],null,[20],{"name":21,"role":22,"phone":23,"phoneExt":18,"email":24},"Amélie LEVESQUE, MD","CONTACT","+33240083912","amelie.levesque@chu-nantes.fr",[26],{"facility":5,"status":18,"city":27,"state":18,"zip":18,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"Nantes","France","FR",{"type":31,"coordinates":32},"Point",[33,34],-1.55336,47.21725,{"lat":34,"lon":33},[37],{"name":5,"role":22,"phone":18,"phoneExt":18,"email":18},{"type":39,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100641680","evolution-of-different-sensitivity-levels-in-patients-with-chronic-neuropathic-pain-in-the-pelvi-perineal-region-after-treatment-with-high-concentration-capsaicin-patches-100641680",false,"NCT07660510","Evolution of Different Sensitivity Levels in Patients With Chronic Neuropathic Pain in the Pelvi-perineal Region After Treatment With High-concentration Capsaicin Patches","CAPSASENS","Inclusion Criteria:\n\n* Men or women ≥ 18 years old.\n* Patients suffering from chronic pelvi-perineal neuralgia (\\>3 months) with a DN4 score ≥4 at the inclusion visit, with or without symptoms of central sensitization, and with an indication for topical treatment with high-concentration capsaicin patch (PCHC).\n* Patients who have signed the informed consent form for the study at the inclusion visit.\n* Women must meet one of the following criteria at the time of inclusion:\n* Use adequate contraceptive measures;\n* or Be postmenopausal (aged over 50 years with amenorrhea for at least 12 months after discontinuation of all exogenous hormonal treatments);\n* or (If aged under 50 years) have been amenorrheic for at least 12 months after discontinuation of exogenous hormonal treatments, with luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels consistent with postmenopausal levels;\n* or Have undergone irreversible surgical sterilization (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), with documentation of the procedure.\n\nExclusion Criteria:\n\n* Patients under guardianship, curatorship, or legal protection.\n* Pregnant or breastfeeding women.\n* Patients with contraindications to the use of the high-concentration capsaicin patch (PCHC): application on damaged skin, hypersensitivity to any of its components.\n* Patients simultaneously starting a treatment that may influence central sensitization (e.g., antidepressants, antiepileptics, psychotherapy, physical activity, transcutaneous electrical nerve stimulation).\n* Patients not affiliated with the French Social Security system.\n* Patients with insufficient cooperation and\u002For understanding to strictly comply with the protocol requirements.\n* Patients who have taken analgesics within the 12 hours prior to measurements.","ALL","18 Years",{"count":50,"type":51},30,"ESTIMATED","INTERVENTIONAL",[54],"NA","The primary objective of this study will be to demonstrate a change in pain sensitization parameters before and after the application of the high-concentration capsaicin patch.",[57,58],"Neuropathic Pain","Nociplastic Pain",[60,61,62,63],"Sensitization","8% capsaicin patch","Quantitative Sensory Testing","Temporal Summation","NOT_YET_RECRUITING","2026-06-15",{"date":67,"type":68},"2026-06-22","ACTUAL",{"date":70,"type":51},"2026-09-01",{"date":72,"type":51},"2028-03-01",{"name":5,"class":6},1]